|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:academic_programs
|
gptkb:Dr._John_Smith
|
|
gptkbp:acquired_by
|
gptkb:Celgene_Corporation
|
|
gptkbp:acquisition
|
$9 billion
|
|
gptkbp:acquisition_year
|
gptkb:2018
|
|
gptkbp:advertising
|
gptkb:Dr._Michael_Brown
|
|
gptkbp:ceo
|
gptkb:Hans_Bishop
|
|
gptkbp:clinical_trial
|
gptkb:CAR_T-cell_therapy
Phase 1
Phase 2
Phase 3
|
|
gptkbp:conducts_research_on
|
gptkb:Dr._David_Chang
|
|
gptkbp:focus
|
cancer immunotherapy
|
|
gptkbp:founded
|
gptkb:2013
|
|
gptkbp:founder
|
gptkb:Hans_Bishop
|
|
gptkbp:has_authority_over
|
gptkb:Dr._Emily_White
|
|
gptkbp:head_of_commercial_operations
|
gptkb:Dr._Hans_Bishop
|
|
gptkbp:head_of_state
|
gptkb:Dr._Sarah_Johnson
gptkb:Dr._Mark_J._Gilbert
gptkb:Dr._Richard_A._Miller
gptkb:Dr._Robert_A._Nelsen
|
|
gptkbp:headquarters
|
gptkb:Seattle,_Washington
|
|
gptkbp:healthcare
|
gptkb:2017
gptkb:2018
gptkb:2019
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Juno Therapeutics
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:key_people
|
gptkb:Catherine_A._Mackey
gptkb:Mark_J._Gilbert
gptkb:Robert_A._Nelsen
gptkb:David_Chang
gptkb:Richard_A._Miller
|
|
gptkbp:partnership
|
gptkb:Celgene_Corporation
gptkb:Kite_Pharma
gptkb:Bristol-Myers_Squibb
gptkb:Novartis
|
|
gptkbp:product
|
JCAR017
JCAR014
JCAR069
|
|
gptkbp:regulatory_compliance
|
gptkb:Dr._Catherine_A._Mackey
|
|
gptkbp:research_focus
|
gptkb:CAR_T-cell_therapy
gptkb:Cell
gene editing
|
|
gptkbp:stock_symbol
|
gptkb:JUNO
|
|
gptkbp:supply_chain
|
gptkb:Dr._Jane_Doe
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.junotherapeutics.com
|
|
gptkbp:bfsParent
|
gptkb:Bristol-Myers_Squibb
gptkb:Celgene
|
|
gptkbp:bfsLayer
|
4
|